Protocol Cervical Screening™

A combined cervical screening test that pairs HPV DNA testing with a Pap smear for enhanced detection accuracy. Designed to identify high-risk HPV strains and precancerous cervical changes earlier than standard Pap testing alone.

The PROTOCOL Cervical Screening™ is Protocol Health's dedicated women's health panel, combining two complementary diagnostic methods — HPV DNA typing and liquid-based cytology (Pap smear) — into a single, streamlined appointment. HPV DNA testing detects the presence of high-risk human papillomavirus genotypes (particularly HPV 16 and HPV 18, which account for the majority of cervical cancer cases) at a molecular level, before abnormal cells are detectable by cytology alone. The co-test approach is recommended by major international gynaecological societies because it significantly raises sensitivity for high-grade cervical intraepithelial neoplasia (CIN 2/3) and early carcinoma compared to either test used independently. Samples are collected by a trained clinician in a brief appointment and processed in an accredited Singapore laboratory. Results include both the HPV genotyping report and the cytology assessment, with a clear risk stratification and recommended follow-up pathway provided by the clinic's physicians. Women who test HPV-negative with normal cytology face a very low risk of developing cervical cancer in the subsequent five years, allowing extended screening intervals. For women with abnormal results, the clinic provides referral pathways and can coordinate further colposcopy or specialist assessment. Protocol Health's cervical screening service is available as a standalone appointment or as an add-on to the Core Health Test, making it easy to incorporate into an annual preventive health visit. It is recommended for all women aged 25 and above, or earlier for those with risk factors such as early sexual debut, multiple partners, or immunosuppression.